Last updated on December 2019

ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Brief description of study

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-Nave Subjects with Progressive High Grade Glioma Following Prior Therapy and Subjects with Newly Diagnosed Glioblastoma. ABI-009 will be tested as single agent or in combination with standard therapies

Clinical Study Identifier: NCT03463265

Find a site near you

Start Over

St. Joseph Heritage Healthcare

Fullerton, CA United States
  Connect »

Hoag Memorial Hospital Presbyterian

Newport Beach, CA United States
  Connect »

John Wayne Cancer Institute

Santa Monica, CA United States
  Connect »